The Cigna-NCCN collaboration will benefit about 12.5 million members.
As part of the company's coverage policy development, Cigna is using the NCCN Guidelines(R) and the NCCN Compendium(R) as references in the appropriate choice for the treatment of people with cancer in the United States.
Cigna is using National Comprehensive Cancer Network® (NCCN®) Content as a resource for oncology coverage policy development and updates for the company's more than 840,000 providers throughout the United States.
"Cigna recognizes the important role that NCCN has in establishing standards and guidance for care in the area of cancer screening, diagnosis, treatment, and surveillance," said Julie B. Kessel, MD, Cigna's Senior Medical Director for Coverage Policy.
Read the report: http://cnnmon.ie/1vuxXYw
Source: CNN Money
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices
February 29th 2024ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.
Read More